XML 42 R31.htm IDEA: XBRL DOCUMENT v3.5.0.2
Goodwill And Other Intangibles (Tables)
 9 Months Ended
Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of changes in the carrying amount of goodwill
Changes in the carrying amount of our goodwill for the nine months ended September 30, 2016 were as follows (in thousands):
 
Carrying Amount
 
U.S. Branded Pharmaceuticals
 
U.S. Generic Pharmaceuticals
 
International Pharmaceuticals
 
Total
Balance as of December 31, 2015:
 
 
 
 
 
 
 
Goodwill
$
1,676,276

 
$
5,789,934

 
$
592,424

 
$
8,058,634

Accumulated impairment losses
(673,500
)
 
—

 
(85,780
)
 
(759,280
)
Balance as of December 31, 2015
$
1,002,776

 
$
5,789,934

 
$
506,644

 
$
7,299,354

Measurement period adjustments
16,518

 
75,750

 
1,366

 
93,634

Effect of currency translation on gross balance
—

 
—

 
19,732

 
19,732

Effect of currency translation on accumulated impairment
—

 
—

 
(1,100
)
 
(1,100
)
Balance as of September 30, 2016:
 
 
 
 
 
 
 
Goodwill
$
1,692,794

 
$
5,865,684

 
$
613,522

 
$
8,172,000

Accumulated impairment losses
(673,500
)
 
—

 
(86,880
)
 
(760,380
)
 
$
1,019,294

 
$
5,865,684

 
$
526,642

 
$
7,411,620
Schedule of other intangible assets
The following is a summary of other intangible assets held by the Company at September 30, 2016 and December 31, 2015 (in thousands):
Cost basis:
Balance as of December 31, 2015
 
Acquisitions
(1)
 
Impairments
(2)
 
Other
(3)
 
Effect of Currency Translation
 
Balance as of September 30, 2016
Indefinite-lived intangibles:
 
 
 
 
 
 
 
 
 
 
 
In-process research and development
$
1,742,880

 
$
(114,200
)
 
$
(55,100
)
 
$
(138,456
)
 
$
2,594

 
$
1,437,718

Total indefinite-lived intangibles
$
1,742,880

 
$
(114,200
)
 
$
(55,100
)
 
$
(138,456
)
 
$
2,594

 
$
1,437,718

Definite-lived intangibles:
 
 
 
 
 
 
 
 
 
 
 
Licenses (weighted average life of 12 years)
$
676,867

 
$
—

 
$
—

 
$
(211,147
)
 
$
—

 
$
465,720

Customer relationships (weighted average life of 15 years)
11,318

 
—

 
(3,460
)
 
(7,858
)
 
—

 
—

Tradenames (weighted average life of 12 years)
7,537

 
—

 
—

 
—

 
(127
)
 
7,410

Developed technology (weighted average life of 12 years)
6,731,573

 
148,891

 
(216,194
)
 
123,618

 
24,263

 
6,812,151

Total definite-lived intangibles (weighted average life of 12 years)
$
7,427,295

 
$
148,891

 
$
(219,654
)
 
$
(95,387
)
 
$
24,136

 
$
7,285,281

Total other intangibles
$
9,170,175

 
$
34,691

 
$
(274,754
)
 
$
(233,843
)
 
$
26,730

 
$
8,722,999

 
 
 
 
 
 
 
 
 
 
 
 
Accumulated amortization:
Balance as of December 31, 2015
 
Amortization
 
Impairments
 
Other
 
Effect of Currency Translation
 
Balance as of September 30, 2016
Definite-lived intangibles:
 
 
 
 
 
 
 
 
 
 
 
Licenses
$
(508,225
)
 
$
(37,142
)
 
$
—

 
$
211,147

 
$
—

 
$
(334,220
)
Customer relationships
(7,858
)
 
—

 
—

 
7,858

 
—

 
—

Tradenames
(6,544
)
 
(66
)
 
—

 
—

 
19

 
(6,591
)
Developed technology
(818,606
)
 
(598,853
)
 
—

 
13,201

 
(2,352
)
 
(1,406,610
)
Total definite-lived intangibles
$
(1,341,233
)
 
$
(636,061
)
 
$
—

 
$
232,206

 
$
(2,333
)
 
$
(1,747,421
)
Total other intangibles
$
(1,341,233
)
 
$
(636,061
)
 
$
—

 
$
232,206

 
$
(2,333
)
 
$
(1,747,421
)
Net other intangibles
$
7,828,942

 
 
 
 
 
 
 
 
 
$
6,975,578

__________
(1)
Includes intangible assets acquired through the acquisition of Voltaren® Gel and other business combinations in addition to the capitalization of payments relating to XIAFLEX®, offset by measurement period adjustments relating to the Par acquisition.
(2)
Includes the impairment of certain intangible assets of our U.S. Generic Pharmaceuticals segment of $169.6 million, our U.S. Branded Pharmaceuticals segment of $72.8 million, our International Pharmaceuticals segment of $16.2 million and the impairment of certain intangible assets in connection with the wind down of our Astora business, with a net impairment of approximately $16.3 million, which is reported as Discontinued operations, net of tax in the Condensed Consolidated Statements of Operations for the nine months ended September 30, 2016. See Note 3. Discontinued Operations and Held for Sale for further information relating to the Astora wind down.
(3)
Includes the removal of approximately $221.9 million of fully amortized intangible assets relating to expired or terminated licensing agreements in our U.S. Branded Pharmaceuticals segment, including the 2008 Voltaren® Gel agreement, described in Note 10. License and Collaboration Agreements, NatestoTM, described in Note 5. Acquisitions of our Annual Report on Form 10-K for the year ended December 31, 2015, and STENDRA®, described in Note 10. Goodwill and Other Intangibles of our Annual Report on Form 10-K for the year ended December 31, 2015. In addition, $10.0 million of fully amortized assets were removed in connection with the wind down of our Astora business described above. Additionally, certain IPR&D assets of $138.5 million were placed in service and transferred into developed technology, while certain other developed technology assets were removed due to their sale or disposal during the period presented.
Schedule of future amortization expense
Estimated amortization of intangibles for the five fiscal years subsequent to December 31, 2015 is as follows (in thousands):
2016
$
824,062

2017
$
725,659

2018
$
637,623

2019
$
575,060

2020
$
546,598
Schedule of changes in gross carrying amount of other intangible assets
Changes in the gross carrying amount of our other intangibles for the nine months ended September 30, 2016 were as follows (in thousands):
 
Gross Carrying Amount
December 31, 2015
$
9,170,175

Capitalization of payments relating to XIAFLEX®
12,008

Voltaren® Gel acquisition
159,000

Other acquisitions
18,183

Sale of certain International Pharmaceuticals intangible assets
(1,959
)
Impairment of certain U.S. Branded Pharmaceuticals intangible assets
(72,814
)
Impairment of certain U.S. Generic Pharmaceuticals intangible assets
(169,576
)
Impairment of certain International Pharmaceuticals intangible assets
(16,077
)
Impairment of certain Astora intangible assets
(26,318
)
Measurement period adjustments relating to acquisitions closed during 2015 (NOTE 5)
(154,500
)
Removal of fully amortized intangible assets relating to expired or terminated licensing agreements
(221,853
)
Effect of currency translation
26,730

September 30, 2016
$
8,722,999